Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ11805MR)

This product GTTS-WQ11805MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Breast Cancer, Colorectal Cancer (CRC), Non-Small Cell Lung Cancers (NSCLC), Gastric Cancer research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ11805MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2813MR IVTScrip™ mRNA-Anti-ADCYAP1R1, AMG-301(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA AMG-301
GTTS-WQ14740MR IVTScrip™ mRNA-Anti-CD19, SGN-19A(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SGN-19A
GTTS-WQ12947MR IVTScrip™ mRNA-Anti-TNFRSF12A, PDL 192(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA PDL 192
GTTS-WQ5256MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CB-6
GTTS-WQ13315MR IVTScrip™ mRNA-Anti-TFPI, PF-06741086(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA PF-06741086
GTTS-WQ9197MR IVTScrip™ mRNA-Anti-FOLR1, IMGN853(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IMGN853
GTTS-WQ9773MR IVTScrip™ mRNA-Anti-PDCD1, JS001(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA JS001
GTTS-WQ11837MR IVTScrip™ mRNA-Anti-LAG3, MK-4280(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MK-4280
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW